Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: Results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

Journal of the Peripheral Nervous System

Volumn 18, Issue 2, 2013, Pages 130-140

  Léger, Jean Marc ^a   De Bleecker, Jan L ^b   Sommer, Claudia ^c   Robberecht, Wim ^d   Saarela, Mika ^e   Kamienowski, Jerzy ^f   Stelmasiak, Zbigniew ^g   Mielke, Orell ^h   Tackenberg, Björn ⁱ   Shebl, Amgad ^h   Bauhofer, Artur ^h   Zenker, Othmar ^h   Merkies, Ingemar S J ^j  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AZ St Lucas   (Belgium)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f Wojewodzki Szpital Specjalistyczny   (Poland)

^g Kliniczny Nr 1   (Poland)

^h CSL BEHRING GMBH   (Germany)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

chronic inflammatory demyelinating polyneuropathy; INCAT; IVIG; PRIMA; Privigen

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CONTUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GRIP STRENGTH; HEADACHE; HEMOLYSIS; HUMAN; HYPERTENSION; LEUKOPENIA; LIMB PAIN; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SCORING SYSTEM; SCREENING; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84879327668     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12017     Document Type: Article

References (25)

1. Baxley A, Akhtari M, (2011). Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 11: 1663-1667.
2. Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A, (2008). Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 48: 1598-1601.
3. Funfgeld EW, (1966). The vigorimeter: for measurement of the strength of the hand and simulation testing. Dtsch Med Wochenschr 91: 2214-2216.
4. Hahn AF, Bolton CF, Zochodne D, Feasby TE, (1996). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119: 1067-1077.
5. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A,; Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195-201.
6. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
7. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15: 1-9.
8. Kleyweg RP, van der Meche FG, Schmitz PI, (1991). Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14: 1103-1109.
9. Koller H, Kieseier BC, Jander S, Hartung HP, (2005). Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352: 1343-1356.
10. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA, (2010). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 67: 802-807.
11. Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ, (2009). Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73: 39-45.
12. Lunn MP, Leger JM, Merkies IS, Van den Bergh P, van Schaik IN, Inflammatory Neuropathy Consortium; ENMC (2008). 151st ENMC international workshop: Inflammatory Neuropathy Consortium 13th-15th April 2007, Schiphol, The Netherlands. Neuromuscul Disord 18: 85-89.
13. McCombe PA, Pollard JD, McLeod JG, (1987). Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110: 1617-1630.
14. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ, (2001). Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445-449.
15. Merkies IS, Lauria G, (2006). 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 16: 149-156.
16. Merkies IS, Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung HP, Latov N, van Doorn PA, Deng C, (2010a). Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 15: 208-215.
17. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C, (2010b). Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81: 1194-1199.
18. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M, (2012). Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11: 493-502.
19. Otremba B, Slawik HR, Tschechne B, Lotichius P, Pfruender D, (2012). Efficacy and tolerability of Privigen® (IgPro10) in primary and secondary immunodeficiencies-A multicenter observational study. In: Abstracts of the 15th Biennial Meeting of the European Society for Immunodeficiency. October 3-6, 2012. Florence, Italy. J Clin Immunol 32 (Suppl 1): S2-S407.
20. Padmore RF, (2012). Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci 46: 93-96.
21. Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG, Zenker O, Kiessling P, (2009). Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 14: 227-236.
22. Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J, (2009). Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 29: 137-144.
23. Thompson N, Choudhary P, Hughes RA, Quinlivan RM, (1996). A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 243: 280-285.
24. Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS, (2013). Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG-the ICE Study. Eur J Neurol 20: 748-755.
25. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF, (1993). Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56: 36-39.